Girentuximab
Based on 1 publication(s) in Google Scholar
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.90%
- CAS No.: 916138-87-9
- 분자량:144.62 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Girentuximab
More
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
CA IX |
In Vitro
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Carbonic Anhydrase 9 Protein, Canine (HEK293, His, HY-P75454) can bind Girentuximab. The EC50 for this effect is 26.65 ng/mL. -
Flow cytometric analysis of 1.5×106 HT-29 cells with Girentuximab (HY-P99023, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 916138-87-9
-
Appearance Liquid
-
분자량 144.62 kDa
-
Color Colorless to light yellow
-
SMILES
[Girentuximab]
-
Synonyms
G250; cG250
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Cancer
Carbonic anhydrase-9-targeted near-infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma. [Abstract]2025 Jun 15;156(12):2377-2388. PMID: 39936451
순도&문서
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)